Kraaijenvanger, Eline J.
Banaschewski, Tobias
Eickhoff, Simon B.
Holz, Nathalie E.
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DFG HO 5674/2-1, GRK2350/1)
Radboud University (Radboud Excellence Fellowship)
Zentralinstitut für Seelische Gesundheit (ZI)
Article History
Received: 12 October 2022
Accepted: 19 September 2023
First Online: 2 October 2023
Competing interests
: EJK, NEH and SBE report no financial relationships with commercial interests. TB served in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Lundbeck, Medice, Novartis and Shire. He received conference support or speaker’s fees from Lilly, Medice, Novartis and Shire. He has been involved in clinical trials conducted by Shire and Viforpharma. He received royalties from Hogrefe, Kohlhammer, CIP Medien and Oxford University Press. All other authors do not have any competing interest to declare.